Publications

LJIC 2026 – An Ultrasensitive, Multiplex Immune Panel for Profiling Inflammatory and Autoimmune Disease Biomarkers

Product:

NULISAseq Immune 340

Topic:

Autoimmune

Disease Area:

Cancer, IBD, RA, Sepsis, SLE

Sample Type:

Plasma, Serum

Abstract

Profiling a full spectrum of biomarkers involved in inflammatory, autoimmune, and infectious disease remains a major challenge for diagnostic and therapeutic development, largely because existing multiplex platforms lack the sensitivity to capture proteins across a wide range of concentrations in blood. To meet this need, we developed the NULISAseq Immune 340 Panel, enabling simultaneous quantification of approximately 340 proteins spanning apoptosis, immune checkpoints, complement activation, and disease-associated pathways relevant to systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), sepsis, and cancer.

The assay was optimized for plasma and serum and characterized for precision, reproducibility, detectability, specificity, and dilution linearity. Median intra- and inter-plate CVs were below 10%, over 90% of targets showed strong dilutional linearity (R² > 0.9) and >50% detectability with strong signal-to-noise ratio in plasma, and cross-reactivity remained under 1%. Applied to SLE serum and RA plasma cohorts, the panel revealed condition-specific signatures aligned with known disease biology, including elevated interferon and cell death/inflammasome markers in SLE, and higher levels of markers associated with TNF, IL-6/JAK-STAT, and Th17/IL-23 pathway activation in RA.

The NULISAseq™ Immune 340 Panel combines breadth, sensitivity, and reproducibility in a single assay, offering a powerful tool for immune pathway characterization, patient stratification, and early disease detection across diverse conditions.

View Poster

Authors and Affiliations

Xiao-Jun Ma1, Haiyan Wu1, Roopa Comandur1, Victoria Torres1, Joanne Beer1, Kavita Tirumale1, Aaryan Virani1, Ankith Narayan1, Jinwei Du1, Mikhail Levit2, Yao Chen2, Pavithra Krishnaswami2, Joseph DeBettencourt2, Sean Kim1, HaYeun Ji1, Niyati Jhaveri1, Xiaolei Qiu1, Bingqing Zhang1, Yuling Luo1

1Alamar Biosciences Inc., Fremont, California, USA
2Sanofi, Cambridge, Massachusetts, USA

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.